Please assess the completion status of the following clinical trial:

Trial Title: HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Plasma HIV-1 RNA ≥ 1000 copies/ml at Screening~* Treatment experience with antiretroviral therapies (excluding integrase inhibitors)~* Screening PHENOSENSE Entry indicating BMS-626529 inhibitory concentration (IC)50 \< 0.1 μM~* Cluster of differentiation (CD)4+ T-cell count \> 50 cells/mm3~Exclusion Criteria:~* History (or evidence at Screening) of genotypic resistance to any component of the study regimen \[ Tenofovir Disoproxil Fumarate (TDF), Atazanavir (ATV), Raltegravir (RAL)\]~* Certain laboratory and electrocardiogram (ECG) values

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A: BMS-663068 (400mg) + Raltegravir + Tenofovir (Type: EXPERIMENTAL): Treatment Group 1
- Arm B: BMS-663068 (800 mg) + Raltegravir + Tenofovir (Type: EXPERIMENTAL): Treatment Group 2
- Arm C: BMS-663068 (600 mg) + Raltegravir + Tenofovir (Type: EXPERIMENTAL): Treatment Group 3
- Arm D: BMS-663068 (1200 mg) + Raltegravir + Tenofovir (Type: EXPERIMENTAL): Treatment Group 4
- Arm E: Atazanavir + Ritonavir + Raltegravir + Tenofovir (Type: ACTIVE_COMPARATOR): Treatment Group 1 (reference arm)

Based on this trial design, predict the completion outcome and termination type (if applicable).